1. Home
  2. PODD vs DGX Comparison

PODD vs DGX Comparison

Compare PODD & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PODD
  • DGX
  • Stock Information
  • Founded
  • PODD 2000
  • DGX 1967
  • Country
  • PODD United States
  • DGX United States
  • Employees
  • PODD N/A
  • DGX N/A
  • Industry
  • PODD Medical/Dental Instruments
  • DGX Medical Specialities
  • Sector
  • PODD Health Care
  • DGX Health Care
  • Exchange
  • PODD Nasdaq
  • DGX Nasdaq
  • Market Cap
  • PODD 23.8B
  • DGX 20.5B
  • IPO Year
  • PODD 2007
  • DGX 1996
  • Fundamental
  • Price
  • PODD $340.29
  • DGX $180.70
  • Analyst Decision
  • PODD Strong Buy
  • DGX Buy
  • Analyst Count
  • PODD 18
  • DGX 15
  • Target Price
  • PODD $334.50
  • DGX $185.40
  • AVG Volume (30 Days)
  • PODD 532.2K
  • DGX 698.2K
  • Earning Date
  • PODD 11-06-2025
  • DGX 10-21-2025
  • Dividend Yield
  • PODD N/A
  • DGX 1.77%
  • EPS Growth
  • PODD N/A
  • DGX 12.66
  • EPS
  • PODD 3.32
  • DGX 8.35
  • Revenue
  • PODD $2,359,500,000.00
  • DGX $10,522,000,000.00
  • Revenue This Year
  • PODD $29.18
  • DGX $11.12
  • Revenue Next Year
  • PODD $18.09
  • DGX $3.41
  • P/E Ratio
  • PODD $102.63
  • DGX $21.68
  • Revenue Growth
  • PODD 26.00
  • DGX 12.58
  • 52 Week Low
  • PODD $225.37
  • DGX $146.17
  • 52 Week High
  • PODD $353.50
  • DGX $185.62
  • Technical
  • Relative Strength Index (RSI)
  • PODD 59.53
  • DGX 52.20
  • Support Level
  • PODD $336.00
  • DGX $179.77
  • Resistance Level
  • PODD $351.94
  • DGX $185.05
  • Average True Range (ATR)
  • PODD 8.16
  • DGX 2.58
  • MACD
  • PODD -1.50
  • DGX -0.19
  • Stochastic Oscillator
  • PODD 46.37
  • DGX 45.69

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

About DGX Quest Diagnostics Incorporated

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Share on Social Networks: